Research
Hormonal
Recent patents emphasize the development of GLP-1 receptor agonists (GLP-1RAs) for oral delivery and improved weight reduction effects.
Practitioners should consider the potential of new GLP-1RAs that are orally administered and may enhance weight loss.
StrongSupportsmedium confidence
In recent years, patents have emphasized two main goals for developing GLP-1RAs drugs: oral delivery and improved weight reduction effects.
Why this rating
The information is derived from a comprehensive review of patents.
Source
An updated patent review of GLP-1 receptor agonists (2020-present)
Weiwen Lu et al. · Expert Opinion on Therapeutic Patents · 2023
reviewCited 17×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →